Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24906687 | 1.00 | MEN1 (0.33) | MEN1KMT2ACRBNALDH1A1CA12 | |
| SCHEMBL26030157 | 0.94 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL26852355 | 0.92 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL26016243 | 0.84 | LTA4H (0.37) | MEN1KMT2ACRBNCA12CA1 | |
| SCHEMBL26133563 | 0.83 | NOS3 (0.41) | KMT2ACRBNCA12CA1CA2 | |
| SCHEMBL26133569 | 0.83 | NOS3 (0.41) | KMT2ACRBNCA12CA1CA2 | |
| SCHEMBL31297097 | 0.83 | MEN1 (0.38) | MEN1KMT2ACRBNCA12CA1 | |
| SCHEMBL26848393 | 0.83 | LTA4H (0.38) | CRBNALDH1A1 | |
| SCHEMBL30980666 | 0.82 | CRBN (0.37) | MEN1KMT2ACRBNALDH1A1CA12 | |
| SCHEMBL26502517 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | MEN1 2314/4885KMT2A 4146/4885CRBN 963/4885 |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | MEN1 3521/4885KMT2A 2800/4885CRBN 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.